Skin autofluorescence, a non-invasive marker for AGE accumulation, is associated with the degree of atherosclerosis

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Den Dekker, Martijn A M ^a   Zwiers, Marjan ^a   Van Den Heuvel, Edwin R ^a   De Vos, Lisanne C ^a   Smit, Andries J ^a   Zeebregts, Clark J ^a   Oudkerk, Matthijs ^a   Vliegenthart, Rozemarijn ^a   Lefrandt, Joop D ^a   Mulder, Douwe J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY VESSELS; DIABETES MELLITUS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; OPTICAL IMAGING; PLAQUE, ATHEROSCLEROTIC; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 84893453901     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083084     Document Type: Article

References (39)

1. Libby P (2002) Inflammation in atherosclerosis. Nature 420: 868-874.
2. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP (1998) AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. the AGE concept. Cardiovasc Res 37: 586-600. (Pubitemid 28231153)
3. Kume S, Takeya M, Mori T, Araki N, Suzuki H, et al. (1995) Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol 147: 654-667.
4. Park L, Raman KG, Lee KJ, Lu Y, Ferran Jr LJ, et al. (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4: 1025-1031. (Pubitemid 28417334)
5. Meerwaldt R, Links T, Zeebregts C, Tio R, Hillebrands J, et al. (2008) The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc Diabetol 7: 29.
6. Hricik DE, Wu YC, Schulak JA, Friedlander MA (1996) Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation. Clin Transplant 10: 568-573. (Pubitemid 27010902)
7. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, et al. (2004) Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 47: 1324-1330. (Pubitemid 39093330)
8. Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, et al. (2005) Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 16: 3687-3693. (Pubitemid 46211290)
9. den Hollander NC, Mulder DJ, Graaff R, Thorpe SR, Baynes JW, et al. (2007) Advanced glycation end products and the absence of premature atherosclerosis in glycogen storage disease ia. J Inherit Metab Dis 30: 916-923. (Pubitemid 350263132)
10. Januszewski AS, Sachithanandan N, Karschimkus C, O'Neal DN, Yeung CK, et al. (2012) Non-invasive measures of tissue autofluorescence are increased in type 1 diabetes complications and correlate with a non-invasive measure of vascular dysfunction. Diabet Med 29: 726-733.
11. Meerwaldt R, Lutgers HL, Links TP, Graaff R, Baynes JW, et al. (2007) Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 30: 107-112. (Pubitemid 46052507)
12. Mulder DJ, van Haelst PL, Gross S, de Leeuw K, Bijzet J, et al. (2008) Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Atherosclerosis 197: 217-223. (Pubitemid 351273241)
13. Mulder DJ, van Haelst PL, Graaff R, Gans RO, Zijlstra F, et al. (2009) Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events. Neth Heart J 17: 162-168.
14. Lutgers HL, Graaff R, de Vries R, Smit AJ, Dullaart RP (2010) Carotid artery intima media thickness associates with skin autofluoresence in non-diabetic subjects without clinically manifest cardiovascular disease. Eur J Clin Invest 40: 812-817.
15. Noordzij MJ, Lefrandt JD, Loeffen EA, Saleem BR, Meerwaldt R, et al. (2012) Skin autofluorescence is increased in patients with carotid artery stenosis and peripheral artery disease. Int J Cardiovasc Imaging 28: 431-438.
16. de Vos LC, Noordzij MJ, Mulder DJ, Smit AJ, Lutgers HL, et al. (2013) Skin autofluorescence as a measure of advanced glycation end product deposition is elevated in peripheral artery disease. Arterioscler Thromb Vasc Biol 33: 131-138.
17. Hollander M, Bots ML, Del Sol AI, Koudstaal PJ, Witteman JC, et al. (2002) Carotid plaques increase the risk of stroke and subtypes of cerebral infarction in asymptomatic elderly: The rotterdam study. Circulation 105: 2872-2877. (Pubitemid 34666101)
18. Oudkerk M, Stillman AE, Halliburton SS, Kalender WA, Mohlenkamp S, et al. (2008) Coronary artery calcium screening: Current status and recommendations from the European society of cardiac radiology and north American society for cardiovascular imaging. Int J Cardiovasc Imaging 24: 645-671.
19. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group (2005) The metabolic syndrome-a new worldwide definition. Lancet 366: 1059-1062. (Pubitemid 41338752)
20. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, et al. (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97: 1837-1847. (Pubitemid 28213628)
21. Levey AS, Greene T, Kusek JW, Beck GJ (2000) A simplified equation to predict glomerular filtration rate from serum creatinine. (abstract). J. Am. Soc. Nephrol. 11: 155A.
22. Mulder DJ, Water TV, Lutgers HL, Graaff R, Gans RO, et al. (2006) Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: An overview of current clinical studies, evidence, and limitations. Diabetes Technol Ther 8: 523-535. (Pubitemid 44946877)
23. Terpstra WF, May JF, Smit AJ, Graeff PA, Meyboom-de Jong B, et al. (2004) Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J Hypertens 22: 1309-1316. (Pubitemid 38888076)
24. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, et al. (2004) Mannheim intima-media thickness consensus. Cerebrovasc Dis 18: 346-349. (Pubitemid 39664263)
25. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M,Jr, etal. (1990) Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15: 827-832. (Pubitemid 20101575)
26. Groen JM, Greuter MJ, Vliegenthart R, Suess C, Schmidt B, et al. (2008) Calcium scoring using 64-slice MDCT, dual source CT and EBT: A comparative phantom study. Int J Cardiovasc Imaging 24: 547-556.
27. Conway BN, Aroda VR, Maynard JD, Matter N, Fernandez S, et al. (2012) Skin intrinsic fluorescence is associated with coronary artery disease in individuals with long duration of type 1 diabetes. Diabetes Care 35: 2331-2336.
28. Tanaka K, Katoh T, Asai J, Nemoto F, Suzuki H, et al. (2010) Relationship of skin autofluorescence to cardiovascular disease in japanese hemodialysis patients. Ther Apheresis Dial 14: 334-340.
29. de leeuw K, Graaff R, de Vries R, Dullaart RP, Smit AJ, et al. (2007) Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus. Rheumatology (UK) 46: 1551-1556.
30. Mitchell JR, Schwartz CJ (1962) Relationship between arterial disease in different sites. A study of the aorta and coronary, carotid, and iliac arteries. Br Med J 1: 1293-1301.
31. Finn AV, Kolodgie FD, Virmani R (2010) Correlation between carotid intimal/medial thickness and atherosclerosis: A point of view from pathology. Arterioscler Thromb Vasc Biol 30: 177-181.
32. Roman MJ, Kizer JR, Best LG, Lee ET, Howard BV, et al. (2012) Vascular biomarkers in the prediction of clinical cardiovascular disease: The strong heart study. Hypertension 59: 29-35.
33. Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD (2005) Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: The st. francis heart study. J Am Coll Cardiol 46: 158-165. (Pubitemid 40905145)
34. Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS (1995) Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area: A histopathologic correlative study. Circulation 92: 2157-2162.
35. Smit AJ, Gerrits EG (2010) Skin autofluorescence as a measure of advanced glycation endproduct deposition: A novel risk marker in chronic kidney disease. Curr Opin Nephrol Hypertens 19: 527-533.
36. Hanssen NM, Engelen L, Ferreira I, Scheijen JL, Huijberts MS, et al. (2013) Plasma levels of advanced glycation endproducts N{epsilon}- (carboxymethyl)lysine, N{epsilon}-(carboxyethyl)lysine, and pentosidine are not independently associated with cardiovascular disease in individuals with or without type 2 diabetes: The Hoorn and CODAM studies. J Clin Endocrinol Metab 98: E1369-73.
37. Tanaka K, Tani Y, Asai J, Nemoto F, Kusano Y, et al. (2012) Skin autofluorescence is associated with severity of vascular complications in Japanese patients with type 2 diabetes. Diabet Med 29: 492-500.
38. Urios P, Grigorova-Borsos AM, Sternberg M (2007) Aspirin inhibits the formation of pentosidine, a cross-linking advanced glycation end product, in collagen. Diabetes Res Clin Pract 77: 337-340. (Pubitemid 46670425)
39. Ishibashi Y, Yamagishi S, Matsui T, Ohta K, Tanoue R, et al. (2012) Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level. Metabolism 61: 1067-1072.